<DOC>
	<DOCNO>NCT02968485</DOCNO>
	<brief_summary>This aim study assess safety tolerability SHR7390 define maximum tolerate dose ( MTD ) SHR7390 patient advance solid tumor . To evaluate pharmacokinetics SHR7390 patient advance solid tumor . To study effect food pharmacokinetic parameter SHR7390 . To assess antitumor activity SHR7390 patient advance solid tumor preliminarily recommend reasonable dosage regimen follow-up clinical trial .</brief_summary>
	<brief_title>Phase I Study SHR7390 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , dose escalation study repeat dos SHR7390 patient advance solid tumor target agent standard therapy . A study cycle define SHR7390 administer daily orally 28 day . Dose limit toxicity ( DLT ) assess first cycle treatment . trial dose escalation design Accelerated Titration Designs initial accelerate phase . significant toxicity DLT observe course treatment , accelerate titration trial terminates subsequent cohort size dose escalation conventional design 3+3 patient . If one adverse event （AE） meet dose limit toxicity ( DLT ) criteria give dose , 3 additional patient enrol dose cohort . If 2 DLTs determine give dose level , dose designate MTD . Additional patient enrol PK evaluation different dose level base preliminary safety tolerability . Multiple blood sample designate time point collect PK evaluation . The safety , tolerability AEs closely monitor throughout study duration . The preliminary effectiveness clinical benefit SHR7390 evaluate single agent . The evaluation effect high-fat , high-calorie meal single-dose pharmacokinetics ( PK ) SHR7390.The design ass food-effect randomize , balance , 2-treatment ( feed vs. fast ) , separated adequate wash-out period .</detailed_description>
	<criteria>The study open male females meet follow inclusion criterion screen baseline participate study . To include participate study patient must : 1 . 1870 year age , woman men ; 2. invalid standard treatment non standard effective treatment patient advance solid tumor diagnose pathology ; 3. Eastern Cooperative Oncology Group （ECOG） General status ( performance status , PS ) 01 ; 4. expect lifetime ≥ 3 month ; 5. organ function must meet following requirement : Adequate bone marrow reserve : include neutrophil absolute count , platelet hemoglobin ; Liver : serum albumin ≥ 3.0 g/dl ; bilirubin , Alanine aminotransferase（ALT）and aspartate aminotransferase（AST）≤ 1.5 x upper limit normal value ( ULN ) , liver metastasis , ALT AST 5x upper limit normal value ( ULN ) ; Kidneys : creatinine clearance ≥ 50 mL/min ( CockcroftGault standard formula）； Heart : leave ventricular ejection fraction ≥ 50 % ; normal Electrocardiograph ( ECG ) correct QT interval（QTc） ; 6 . The damage patient cause treatment restore ; 7 . A agreement use highly effective , nonhormonal form contraception require woman childbearing potential men partner childbearing potential , sterilize surgically , duration study treatment last dose study treatment ; For female patient child bear potential , sterilize surgically , serum human chorionic gonadotropin （HCG） pregnancy test must negative 8 . Written inform consent provide signing informed consent form . Subjects meet criterion list eligible participation study . A patient eligible study participation : 1 . Previous treatment protein kinase MEK inhibitor ; 2 . Use investigational anticancer drug termination investigational drug within last four week ; 3 . Currently possibly receive cancer therapy study period ; 4 . Presence factor influence oral drug ( inability swallow ) presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion drug ; 5 . History retinal vascular occlusion （RVO） central serous retinopathy ; 6 . Visible retinal pathology assess ophthalmologic exam consider risk factor retinal vein thrombosis central serous retinopathy ; 7 . Intraocular pressure &gt; 21mmHg measure tonography glaucoma ; 8 . Tumor metastases central nervous system leptomeningeal metastasis . primary malignancy central nervous system ; 9 . Evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , hepatic , renal cardiac disease ) ; 10 . History acute coronary syndrome ( include unstable angina ) ; 11 . Presence arrhythmia , myocardial ischemia drug intervention . IIIIV stage heart failure define New York Heart Association ( NYHA ) functional classification system . 12 . Medical treatment acute phase infection ; 13. hepatitis B virus（HBV ) hepatitis C virus ( HCV ) infection stage abnormal liver function ; 14 . History immunodeficiency , acquire congenital immunodeficiency disease ; 15 . Psychological , familial , sociological geographical condition permit compliance protocol ; 16 . Unwillingness inability follow procedure outline protocol ; 17 . Concurrent condition investigator 's opinion would jeopardize compliance protocol ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>Protein Kinase MEK inhibitor ( MEKi )</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>